
Taletrectinib Yields Durable Responses, Prolonged PFS in ROS1+ NSCLC
Taletrectinib (Dovbleron) demonstrated positive efficacy, including durable responses, prolonged survival, strong intracranial activity, and a favorable safety profile in patients with ROS1-positive non–small cell lung cancer (NSCLC) regardless of prior …